Endogenous incretin levels and risk of first incident cancer: a prospective cohort study
(2023) In Scientific Reports 13. p.1-11- Abstract
- Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as... (More)
- Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82–0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7c3fd1ac-518e-4831-be8f-74d95d4a768c
- author
- Jujic, Amra LU ; Godina, Christopher LU ; Belting, Mattias LU ; Melander, Olle LU ; Juul Holst, Jens ; Ahlqvist, Emma LU ; Gomez, Maria F LU ; Nilsson, Peter M LU ; Jernström, Helena LU and Magnusson, Martin LU
- organization
-
- EXODIAB: Excellence of Diabetes Research in Sweden
- Cardiovascular Research - Hypertension (research group)
- LUCC: Lund University Cancer Centre
- Cancerepidemiology and radiation
- Tumor microenvironment (research group)
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- EpiHealth: Epidemiology for Health
- Translational Muscle Research (research group)
- eSSENCE: The e-Science Collaboration
- Diabetic Complications (research group)
- Internal Medicine - Epidemiology (research group)
- Epidemiology and pharmacogenetics (research group)
- WCMM-Wallenberg Centre for Molecular Medicine
- publishing date
- 2023-01-07
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scientific Reports
- volume
- 13
- article number
- 382
- pages
- 1 - 11
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:36611045
- scopus:85145864705
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-023-27509-3
- language
- English
- LU publication?
- yes
- id
- 7c3fd1ac-518e-4831-be8f-74d95d4a768c
- date added to LUP
- 2023-01-09 14:11:16
- date last changed
- 2024-05-02 18:53:14
@article{7c3fd1ac-518e-4831-be8f-74d95d4a768c, abstract = {{Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82–0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer.}}, author = {{Jujic, Amra and Godina, Christopher and Belting, Mattias and Melander, Olle and Juul Holst, Jens and Ahlqvist, Emma and Gomez, Maria F and Nilsson, Peter M and Jernström, Helena and Magnusson, Martin}}, issn = {{2045-2322}}, language = {{eng}}, month = {{01}}, pages = {{1--11}}, publisher = {{Nature Publishing Group}}, series = {{Scientific Reports}}, title = {{Endogenous incretin levels and risk of first incident cancer: a prospective cohort study}}, url = {{http://dx.doi.org/10.1038/s41598-023-27509-3}}, doi = {{10.1038/s41598-023-27509-3}}, volume = {{13}}, year = {{2023}}, }